NovoCure Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	93.55	163.77	240.82
Short-Term Investments	354.13	796.11	669.8
Cash & Short-Term Investments	447.67	959.87	910.62
Cash Growth	-53.36%	5.41%	-
Accounts Receivable	89.44	74.23	61.22
Inventory	41.11	35.09	38.15
Other Current Assets	68.51	37.39	24.42
Total Current Assets	646.73	1,107	1,034
Net Property, Plant & Equipment	147	119.59	97.7
Other Long-Term Assets	10.6	14.62	14.02
Total Assets	804.33	1,241	1,146
Accounts Payable	122.23	105.09	94.39
Accrued Expenses	101	93.15	84.72
Current Portion of Long-Term Debt	-	558.16	-
Total Current Liabilities	223.23	756.39	179.12
Long-Term Debt	195.05	97.3	568.82
Long-Term Leases	41.65	19.97	27.42
Other Long-Term Liabilities	3.94	6.94	8.28
Total Long-Term Liabilities	240.63	124.21	604.52
Total Liabilities	463.86	880.61	783.63
Additional Paid-in Capital	1,634	1,520	1,353
Accumulated Other Comprehensive Income	-3.44	-5.5	-5.47
Retained Earnings	-1,290	-1,154	-985.5
Shareholders' Equity	340.47	360.18	362.5
Total Liabilities & Equity	804.33	1,241	1,146
Total Debt	236.69	675.43	596.24
Net Cash (Debt)	210.98	284.44	314.37
Net Cash Growth	-25.83%	-9.52%	-
Net Cash Per Share	1.89	2.64	2.96
Book Value	340.47	360.18	362.5
Book Value Per Share	3.05	3.34	3.41
Tangible Book Value	340.47	360.18	362.5
Tangible Book Value Per Share	3.05	3.34	3.41

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q